BENZONATATE capsule

Šalis: Jungtinės Valstijos

kalba: anglų

Šaltinis: NLM (National Library of Medicine)

Veiklioji medžiaga:

BENZONATATE (UNII: 5P4DHS6ENR) (BENZONATATE - UNII:5P4DHS6ENR)

Prieinama:

Bryant Ranch Prepack

Vartojimo būdas:

ORAL

Recepto tipas:

PRESCRIPTION DRUG

Terapinės indikacijos:

Benzonatate Capsule is indicated for the symptomatic relief of cough. Hypersensitivity to benzonatate or related compounds.

Produkto santrauka:

Benzonatate Capsules USP , 200 mg are available as yellow, oval soft gelatin capsules with '2' imprinted in white ink. NDC: 71335-0031-1: 30 Capsules in a BOTTLE NDC: 71335-0031-2: 100 Capsules in a BOTTLE NDC: 71335-0031-3: 45 Capsules in a BOTTLE NDC: 71335-0031-4: 20 Capsules in a BOTTLE NDC: 71335-0031-5: 15 Capsules in a BOTTLE NDC: 71335-0031-6: 21 Capsules in a BOTTLE NDC: 71335-0031-7: 60 Capsules in a BOTTLE NDC: 71335-0031-8: 50 Capsules in a BOTTLE NDC: 71335-0031-9: 90 Capsules in a BOTTLE Store at 20° to 25°C (68° to 77°F) excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. PROTECT FROM LIGHT. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 9150

Autorizacija statusas:

Abbreviated New Drug Application

Prekės savybės

BENZONATATE- BENZONATATE CAPSULE
BRYANT RANCH PREPACK
----------
BENZONATATE CAPSULES USP, 100 MG AND 200 MG
DESCRIPTION
Benzonatate, a non-narcotic oral antitussive agent, is 2, 5, 8, 11,
14, 17, 20, 23, 26-
nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular
weight of 603.7.
Each Benzonatate Capsules USP contains: Benzonatate, USP 100 mg or 200
mg.
Benzonatate Capsules USP also contain: D&C Yellow 10, gelatin,
glycerin, methylparaben,
propylparaben and titanium dioxide.
CLINICAL PHARMACOLOGY
Benzonatate Capsule acts peripherally by anesthetizing the stretch
receptors located in
the respiratory passages, lungs, and pleura by dampening their
activity and thereby
reducing the cough reflex at its source. It begins to act within 15 to
20 minutes and its
effect lasts for 3 to 8 hours. Benzonatate Capsule has no inhibitory
effect on the
respiratory center in recommended dosage.
INDICATIONS AND USAGE
Benzonatate Capsule is indicated for the symptomatic relief of cough.
CONTRAINDICATIONS
Hypersensitivity to benzonatate or related compounds.
WARNINGS
HYPERSENSITIVITY
Severe hypersensitivity reactions (including bronchospasm,
laryngospasm and
cardiovascular collapse) have been reported which are possibly related
to local
anesthesia from sucking or chewing the capsule instead of swallowing
it. Severe
reactions have required intervention with vasopressor agents and
supportive measures.
PSYCHIATRIC EFFECTS
Isolated instances of bizarre behavior, including mental confusion and
visual
hallucinations, have also been reported in patients taking Benzonatate
Capsule in
combination with other prescribed drugs.
ACCIDENTAL INGESTION AND DEATH IN CHILDREN
Keep Benzonatate Capsules out of reach of children. Accidental
ingestion of
Benzonatate Capsules resulting in death has been reported in children
below age 10.
Signs and symptoms of overdose have been reported within 15-20 minutes
and death
has been reported within one hour of ingestion. If accidental
ingestion occurs, seek
medical attention immediately (see OVERDOSAGE).